Japan
Kyorin signs in-licensing agreement with UBE to grow its new drug pipeline as it chases mid-term deal target.
Kyowa Kirin halts all trials with its OX40-targeting antibody rocatinlimab following Kaposi’s sarcoma cases and Amgen's recent return of the asset.
The Japanese industrial material group expands its global presence with a strategic niche focus on immunology, organ transplantation, and severe infectious diseases.
Asahi Kasei’s €780m acquisition of AiCuris strengthens its anti‑infectives portfolio through immediate Prevymis royalties and the near‑term commercial potential of pritelivir.
Vir enters major global deal worth up to $1.7bn for T-cell engager VIR-5500 in an alliance that will also expand partner Astellas's immuno-oncology pipeline ahead of a major expiry.
Japan has granted the first positive approval recommendations worldwide for two allogenic cell therapies derived from induced pluripotent stem cells, Sumitomo’s raguneprocel for Parkinson’s and Cuorips’ cardiomyocyte patches for heart failure.
Japanese venture Kidswell aiming to progress pediatric cerebral palsy cell therapy in US through new operation.
Major Japanese pharma companies' results for the period ended Dec.31 were marked by generally strong overseas growth for mainstays, boosted by currency effects.
Henlius planning Japanese NDA by end of March 2027 for ES-SCLC and development in several other indications.
US priority review for Japanese firm's first-in-class ADHD drug could result in approval of a new option this year.
While several companies await regulatory approval decisions on their cell therapies in Japan, BioCardia proceeds with discussions on an NDA filing and Innovacel readies an IPO.
Japan's main pharma industry association to assist government agency's early research and drug discovery projects by providing expertise.
The US giant is narrowing its focus on obesity and cancer.
Hisamitsu's CEO is taking the Japanese firm private through a management buyout aimed at securing future growth.
Bain Capital will get back a large chunk of the $3.3bn spent on acquiring Mitsubishi Tanabe through the divestment of the firm’s best-selling product to Shionogi, which will accelerate its diversification away from infectious diseases in the process.
The firm founded by Treg cell discoverer Shimon Sakaguchi is building up its US team and refining R&D strategy and manufacturing processes to create an example and global path for other Japanese ventures.
Oncolys reaches hard-won milestone with an approval filing in Japan for its oncolytic virus therapy telomelysin through the sakigake pathway, with the Japanese venture eyeing its first commercial launch in 2026.
Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.
Setting its focus on oncology, immunology and rare diseases, the firm anticipates double-digit growth for 2030.
While Astellas and Daiichi Sankyo rang in double-digit growth, Eisai offset LOE impact with Leqembi’s performance. Takeda struggled with negative results but announced several growth initiatives.